Antitrust

With new funding from BroadOak Capital Partners, Axol Bioscience is set to expand its revolutionary iPSC-based disease models in the US market.

A major partnership unites three top orthopedic providers, signaling a trend of consolidation and raising questions about patient care and physician autonomy.

A federal court blocked Edwards Lifesciences' key acquisition, citing monopoly fears, yet the company's financial outlook surprisingly improves.

The family of a motorcyclist killed by a Tesla on Autopilot files a wrongful death suit, citing a history of deceptive marketing and known system flaws.

As Triumph Financial preps its Q4 2025 results, investors watch to see if its tech investments can deliver on high growth expectations amid a complex freight market.

The Golden Globes partners with prediction market Polymarket in a bold bid for relevance, but the high-stakes deal brings new scrutiny and ethical questions.

World-renowned Hospital for Special Surgery teams up with Jupiter Medical Center, bringing elite orthopedic care and advanced facilities to South Florida.

Prescryptive and Ilant Health unveil a direct-to-employer model for obesity drugs, promising transparent pricing and better clinical outcomes for employers.

A new study reveals the hidden quality-of-life toll of a common virus on transplant patients, highlighting the urgent need for targeted new therapies.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.

The SEC proposes a landmark update to its 'small entity' definition, a move poised to slash red tape for thousands of firms and foster market competition.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

The fast-food giant launches 'Arches & Ambition' to rebrand its jobs as career launchpads, but how does it stack up against industry labor realities?

Global hygiene firm Essity sees a contentious bondholder lawsuit discontinued with no compensation paid, closing a chapter that tested corporate debt covenants.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Omaha-based Core Bank partners with Kobalt Labs, using AI to slash risk review times from days to minutes and safely accelerate its embedded banking strategy.

With its massive data library and AI platforms, Tempus AI prepares for a pivotal presentation. What will CEO Eric Lefkofsky reveal to investors?

The regional bank sold $360M in low-yield securities, accepting a major one-time loss to reinvest for higher returns and a stronger 2026 outlook.

After a strong year and a landmark acquisition, Waystar's CEO will detail its AI-driven vision for healthcare payments at the J.P. Morgan conference.

With a new HQ and $2M in contracts, Taoping is leveraging AI and government policy to modernize China's aging elevators, but faces investor scrutiny.